Jefferies Group's TVTX Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 4,837 shares of Travere Therapeutics, Inc. (TVTX) worth $143,707, representing 0.00% of the portfolio. First purchased in 2023-Q1, this short-term holding has been held for 8 quarters.
Based on 13F filings, Jefferies Group has maintained this position in TVTX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2024, adding 59,300 shares. Largest reduction occurred in Q3 2024, reducing 59,300 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Travere Therapeutics (TVTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Travere Therapeutics (TVTX) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +1,837 | Add 61.23% | 4,837 | $29.71 |
| Q4 2025 | -1,000 | Reduce 25.00% | 3,000 | $38.21 |
| Q3 2025 | +4,000 | New Buy | 4,000 | $23.90 |
| Q3 2024 | -59,300 | Sold Out | 0 | $0.00 |
| Q1 2024 | +59,300 | New Buy | 59,300 | $7.71 |
| Q2 2023 | -15,000 | Sold Out | 0 | $0.00 |
| Q1 2023 | +15,000 | New Buy | 15,000 | $22.49 |
Jefferies Group's Travere Therapeutics Investment FAQs
Jefferies Group first purchased Travere Therapeutics, Inc. (TVTX) in Q1 2023, acquiring 15,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Travere Therapeutics, Inc. (TVTX) for 8 quarters since Q1 2023.
Jefferies Group's largest addition to Travere Therapeutics, Inc. (TVTX) was in Q1 2024, adding 59,300 shares worth $457,203.
According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 4,837 shares of Travere Therapeutics, Inc. (TVTX), valued at approximately $143,707.
As of the Q1 2026 filing, Travere Therapeutics, Inc. (TVTX) represents approximately 0.00% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Travere Therapeutics, Inc. (TVTX) was 59,300 shares, as reported at the end of Q1 2024.